Study results demonstrate the safety and
feasibility of adoptive immunotherapy using allogeneic
off-the-shelf NK cells in hospitalized patients with COVID at high
risk for progression of disease
DVX201, the first allogeneic NK cell therapy
derived from pooled donor cord blood CD34+ cells, was administered
to 9 patients with no dose limiting toxicities, cytokine release
syndrome or infusion toxicities
WEXFORD,
Pa., Nov. 7, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases,
today announced that results from their Phase 1 study evaluating
DVX201, an allogeneic natural killer (NK) cell therapy, for the
treatment of patients hospitalized with COVID-19 has been accepted
for publication in Molecular Therapy Methods and Clinical
Development.
Results from the clinical trial demonstrated the safety and
feasibility of DVX201 as a potential treatment for patients with
active SARS-CoV-2 infections. The following key findings are
highlighted in the accepted manuscript:
- First Demonstration of Safety: This is the first
known study to demonstrate the safety of adoptive immunotherapy
with allogeneic, off-the-shelf NK cells in patients with active
COVID-19, especially those at high risk for disease
progression.
- Innovative NK Cell Therapy: DVX201 is the first
allogeneic NK cell adoptive immunotherapy used clinically that is
derived from pooled donor cord blood CD34+ cells, offering a
scalable, consistent, and cost-effective solution to barriers in
the allogeneic cell therapy space.
- No Adverse Events: DVX201 infusions were safe and
well-tolerated, with no treatment-related adverse events, including
no cytokine release syndrome (CRS).
- Study Observations: Observations included rapid
improvements in oxygenation, improved pulmonary radiographic
findings, and hospital discharge within days of infusion.
- Future Potential for Viral Therapies: This study
supports the potential of allogeneic NK cell therapy as a scalable,
stockpile-ready antiviral treatment for future viral
pandemics.
" Despite advances in treatment and prevention strategies for
SARS-CoV-2, COVID-19 still results in substantial morbidity in
certain patient populations underscoring the ongoing need for
additional therapeutic options, particularly among immune
compromised individuals," said Joshua
Hill, MD, associate professor and physician at Fred Hutch
Cancer Center and corresponding author of the study. "Although the
study was not designed to assess efficacy, our findings demonstrate
the safety and potential utility of NK cell therapy as a
complementary therapeutic strategy for viral infections in
high-risk patients."
"We are very excited by these results and look forward to
sharing the full findings in Molecular Therapy Methods and
Clinical Development," said Dave
Mehalick, President and CEO of Coeptis Therapeutic. "These
positive results, along with our recently announced expanded
license agreement with Deverra, further strengthens Coeptis' role
in the fight against infectious diseases."
To access the full publication in Molecular Therapy Methods
and Clinical Development, please visit:
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(24)00177-3
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms, which Coeptis is developing with
VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is
designed around maximizing the value of its current product
portfolio and rights through in-license agreements, out-license
agreements and co-development relationships, as well as entering
into strategic partnerships to expand its product rights and
offerings, specifically those targeting cancer and infectious
diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our
management made in connection therewith contain or may contain
"forward-looking statements" (as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended). Forward-looking
statements include statements concerning our plans, objectives,
goals, strategies, future events or performance, and underlying
assumptions, and other statements that are other than statements of
historical facts. When we use words such as "may," "will,"
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to
historical matters, we are making forward-looking statements.
Forward-looking statements are not a guarantee of future
performance and involve significant risks and uncertainties that
may cause the actual results to differ materially and perhaps
substantially from our expectations discussed in the
forward-looking statements. Factors that may cause such differences
include but are not limited to: (1) the inability to maintain the
listing of the Company's securities on the Nasdaq Capital Market;
(2) the risk that the integration of the Deverra licensed assets
will disrupt current plans and operations of the Company; (3) the
inability to recognize the anticipated benefits of the
newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-announces-phase-1-data-on-dvx201-for-covid-19-treatment-has-been-accepted-for-publication-in-molecular-therapy-methods-and-clinical-development-302296125.html
SOURCE Coeptis Pharmaceuticals, Inc.
